Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.
direct-acting antivirals (DAAs)
phylogenetic analysis
resistance-associated substitutions (RAS)
sofosbuvir
velpatasvir
voxilaprevir
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
03
01
2019
revised:
01
02
2019
accepted:
19
02
2019
entrez:
6
4
2019
pubmed:
6
4
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome. Full-genome sequencing was performed on HCV plasma samples with <85% sequence homology of NS3, NS5A, and/or NS5B to HCV genotype (GT) 1-8 reference strains. A total of 14 653 patients with GT1-6 HCV infection were enrolled in clinical studies of sofosbuvir-based regimens. For the majority of the patients, a specific subtype could be assigned based on a close genetic relationship to previously described subtypes. However, for 19 patients, novel subtypes were identified with <85% homology compared with previously described subtypes. These novel subtypes had the following genotypes: 9 in GT2, 5 in GT4, 2 in GT6, and 1 each in GT1, GT3, and GT5. Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12. Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome.
METHODS
METHODS
Full-genome sequencing was performed on HCV plasma samples with <85% sequence homology of NS3, NS5A, and/or NS5B to HCV genotype (GT) 1-8 reference strains.
RESULTS
RESULTS
A total of 14 653 patients with GT1-6 HCV infection were enrolled in clinical studies of sofosbuvir-based regimens. For the majority of the patients, a specific subtype could be assigned based on a close genetic relationship to previously described subtypes. However, for 19 patients, novel subtypes were identified with <85% homology compared with previously described subtypes. These novel subtypes had the following genotypes: 9 in GT2, 5 in GT4, 2 in GT6, and 1 each in GT1, GT3, and GT5. Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12.
CONCLUSIONS
CONCLUSIONS
Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized.
Identifiants
pubmed: 30949527
doi: 10.1093/ofid/ofz076
pii: ofz076
pmc: PMC6440686
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz076Références
Lancet Infect Dis. 2005 Sep;5(9):558-67
pubmed: 16122679
Syst Biol. 2006 Aug;55(4):539-52
pubmed: 16785212
Adv Drug Deliv Rev. 2007 Oct 10;59(12):1242-62
pubmed: 17869377
Antimicrob Agents Chemother. 2010 Aug;54(8):3099-106
pubmed: 20516274
Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96
pubmed: 20516278
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638
J Hepatol. 2011 Jun;54(6):1114-22
pubmed: 21145839
Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203
pubmed: 21746939
J Virol. 2011 Dec;85(23):12334-42
pubmed: 21957306
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68
pubmed: 22430955
PLoS One. 2012;7(6):e39163
pubmed: 22720059
Hepatology. 2014 Jan;59(1):318-27
pubmed: 24115039
N Engl J Med. 2014 May 22;370(21):1993-2001
pubmed: 24795201
Hepatology. 2015 Jan;61(1):77-87
pubmed: 25069599
J Clin Microbiol. 2015 Jul;53(7):2049-59
pubmed: 25878342
N Engl J Med. 2015 Dec 31;373(27):2599-607
pubmed: 26571066
Hepatology. 2016 Sep;64(3):983-5
pubmed: 27177605
Ethiop Med J. 2016 Jan;54(1):1-7
pubmed: 27191024
J Viral Hepat. 2016 Oct;23(10):780-8
pubmed: 27196675
Hepatology. 2016 Oct;64(4):1049-56
pubmed: 27351341
N Engl J Med. 2017 Jun 1;376(22):2134-2146
pubmed: 28564569
J Hepatol. 2018 Apr;68(4):814-826
pubmed: 29229584
J Infect Dis. 2018 Oct 20;218(11):1722-1729
pubmed: 29982508